AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 1st, 2013 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
This agreement is dated December __, 2012 and is by and between HALOZYME THERAPEUTICS, INC., a Delaware corporation (the “Company,” “us,” “we” or “our”), and [Name of Officer] (“you” or “your”).
LOAN AND SECURITY AGREEMENTLoan and Security Agreement • March 1st, 2013 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
THIS AGREEMENT OF MERGER (this “Agreement”), is made and entered into as of March 9, 2004, by and among Global Yacht Services, Inc., a Nevada corporation (the “Parent”), DeliaTroph Pharmaceuticals, Inc. dba Hyalozyme Therapeutics, Inc., a California corporation (the “Company”), and Hyalozyme Acquisition Corporation, a Nevada corporation and a wholly-owned subsidiary of Parent (“Sub” and, together with the Company, the “Constituent Corporations”).
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT AND DISBURSEMENT LETTERLoan and Security Agreement • March 1st, 2013 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT to Loan and Security Agreement and Disbursement Letter (this “Amendment”) is entered into as of February 5, 2013, by and among OXFORD FINANCE LLC (“Oxford”) as collateral agent (in such capacity, the “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement or otherwise a party thereto from time to time including, without limitation, Oxford in its capacity as a Lender, and SILICON VALLEY BANK (in such capacity, each a “Lender” and collectively, the “Lenders”), and HALOZYME THERAPEUTICS, INC., a Delaware corporation, and HALOZYME, INC., a California corporation (individually and collectively, jointly and severally, “Borrower”).
